To develop and validate a deep learning model using multimodal PET/CT imaging for detecting and classifying focal liver lesions (FLL). This study included 185 patients who underwent ¹⁸F-FDG PET/CT imaging at our institution from March 2022 to February 2023. We analyzed serological data and imaging. Liver lesions were segmented on PET and CT, serving as the "reference standard". Deep learning models were trained using PET and CT images to generate predicted segmentations and classify lesion nature. Model performance was evaluated by comparing the predicted segmentations with the reference segmentations, using metrics such as Dice, Precision, Recall, F1-score, ROC, and AUC, and compared it with physician diagnoses. This study finally included 150 patients, comprising 46 patients with benign liver nodules, 51 patients with malignant liver nodules, and 53 patients with no FLLs. Significant differences were observed among groups for age, AST, ALP, GGT, AFP, CA19-9and CEA. On the validation set, the Dice coefficient of the model was 0.740. For the normal group, the recall was 0.918, precision was 0.904, F1-score was 0.909, and AUC was 0.976. For the benign group, the recall was 0.869, precision was 0.862, F1-score was 0.863, and AUC was 0.928. For the malignant group, the recall was 0.858, precision was 0.914, F1-score was 0.883, and AUC was 0.979. The model's overall diagnostic performance was between that of junior and senior physician. This deep learning model demonstrated high sensitivity in detecting FLLs and effectively differentiated between benign and malignant lesions.

To investigate the impact of artificial intelligence (AI) reading digital mammograms in increasing the chance of detecting missed breast cancer, by studying the AI- flagged early morphology indictors, overlooked by the radiologist, and correlating them with the missed cancer pathology types. Mammograms done in 2020-2023, presenting breast carcinomas (n = 1998), were analyzed in concordance with the prior one year's result (2019-2022) assumed negative or benign. Present mammograms reviewed for the descriptors: asymmetry, distortion, mass, and microcalcifications. The AI presented abnormalities by overlaying color hue and scoring percentage for the degree of suspicion of malignancy. Prior mammogram with AI marking compromised 54 % (n = 555), and in the present mammograms, AI targeted 904 (88 %) carcinomas. The descriptor proportion of "asymmetry" was the common presentation of missed breast carcinoma (64.1 %) in the prior mammograms and the highest detection rate for AI was presented by "distortion" (100 %) followed by "grouped microcalcifications" (80 %). AI performance to predict malignancy in previously assigned negative or benign mammograms showed sensitivity of 73.4 %, specificity of 89 %, and accuracy of 78.4 %. Reading mammograms with AI significantly enhances the detection of early cancerous changes, particularly in dense breast tissues. The AI's detection rate does not correlate with specific pathological types of breast cancer, highlighting its broad utility. Subtle mammographic changes in postmenopausal women, not corroborated by ultrasound but marked by AI, warrant further evaluation by advanced applications of digital mammograms and close interval AI-reading mammogram follow up to minimize the potential for missed breast carcinoma.

Gallbladder cancer (GBC) is the most common malignant tumor in the biliary system, characterized by high malignancy, aggressiveness, and poor prognosis. Early diagnosis holds paramount importance in ameliorating therapeutic outcomes. Presently, the clinical diagnosis of GBC primarily relies on clinical-radiological-pathological approach. However, there remains a potential for missed diagnosis and misdiagnose in the realm of clinical practice. We firstly analyzed the blood-based biomarkers, such as carcinoembryonic antigen and carbohydrate antigen 19-9. Subsequently, we evaluated the diagnostic performance of various imaging modalities, including ultrasound (US), endoscopic ultrasound (EUS), computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography/computed tomography (PET/CT) and pathological examination, emphasizing their strengths and limitations in detecting early-stage GBC. Furthermore, we explored the potential of emerging technologies, particularly artificial intelligence (AI) and liquid biopsy, to revolutionize GBC diagnosis. AI algorithms have demonstrated improved image analysis capabilities, while liquid biopsy offers the promise of non-invasive and real-time monitoring. However, the translation of these advancements into clinical practice necessitates further validation and standardization. The review highlighted the advantages and limitations of current diagnostic approaches and underscored the need for innovative strategies to enhance diagnostic accuracy of GBC. In addition, we emphasized the importance of multidisciplinary collaboration to improve early diagnosis of GBC and ultimately patient outcomes. This review endeavoured to impart fresh perspectives and insights into the early diagnosis of GBC.

Bi-parametric magnetic resonance imaging (bpMRI) has become a pivotal modality in the detection and diagnosis of clinically significant prostate cancer (csPCa). Developing AI-based systems to identify csPCa using bpMRI can transform prostate cancer (PCa) management by improving efficiency and cost-effectiveness. However, current state-of-the-art methods using convolutional neural networks (CNNs) and Transformers are limited in learning in-plane and three-dimensional spatial information from anisotropic bpMRI. Their performances also depend on the availability of large, diverse, and well-annotated bpMRI datasets. To address these challenges, we propose the Zonal-aware Self-supervised Mesh Network (Z-SSMNet), which adaptively integrates multi-dimensional (2D/2.5D/3D) convolutions to learn dense intra-slice information and sparse inter-slice information of the anisotropic bpMRI in a balanced manner. We also propose a self-supervised learning (SSL) technique that effectively captures both intra-slice and inter-slice semantic information using large-scale unlabeled data. Furthermore, we constrain the network to focus on the zonal anatomical regions to improve the detection and diagnosis capability of csPCa. We conducted extensive experiments on the PI-CAI (Prostate Imaging - Cancer AI) dataset comprising 10000+ multi-center and multi-scanner data. Our Z-SSMNet excelled in both lesion-level detection (AP score of 0.633) and patient-level diagnosis (AUROC score of 0.881), securing the top position in the Open Development Phase of the PI-CAI challenge and maintained strong performance, achieving an AP score of 0.690 and an AUROC score of 0.909, and securing the second-place ranking in the Closed Testing Phase. These findings underscore the potential of AI-driven systems for csPCa diagnosis and management.

To develop dynamic MRU protocol that focuses on the bladder to capture ureteral jets and to automatically estimate frequency and duration of ureteral jets from the dynamic images. Between February and July 2023, we collected 51 sets of dynamic MRU data from 5 healthy subjects. To capture the entire longitudinal trajectory of ureteral jets, we optimized orientation and thickness of the imaging slice for dynamic MRU, and developed a deep-learning method to automatically estimate frequency and duration of ureteral jets from the dynamic images. Among the 15 sets of images with different slice positioning, the positioning with slice thickness of 25 mm and orientation of 30° was optimal. Of the 36 sets of dynamic images acquired with the optimal protocol, 27 sets or 2529 images were used to train a U-Net model for automatically detecting the presence of ureteral jets. On the other 9 sets or 760 images, accuracy of the trained model was found to be 84.9 %. Based on the results of automatic detection, frequency of ureteral jet in each set of dynamic images was estimated as 8.0 ± 1.4 min^-1, deviating from reference by -3.3 % ± 10.0 %; duration of each individual ureteral jet was estimated as 7.3 ± 2.8 s, deviating from reference by 2.4 % ± 32.2 %. The accumulative duration of ureteral jets estimated by the method correlated well (with coefficient of 0.936) with the bladder expansion recorded in the dynamic images. The proposed method was capable of quantitatively characterizing ureteral jets, potentially providing valuable information on functional status of ureteral peristalsis.

In the diagnosis of patellar instability, three-dimensional (3D) imaging enables measurement of a wide range of metrics. However, measuring these metrics can be time-consuming and prone to error due to conducting 2D measurements on 3D objects. This study aims to measure patellar tilt in 3D and automate it by utilizing a commercial AI algorithm for landmark placement. CT-scans of 30 patients with at least two dislocation events and 30 controls without patellofemoral disease were acquired. Patellar tilt was measured using three different methods: the established method, and by calculating the angle between 3D-landmarks placed by either a human rater or an AI algorithm. Correlations between the three measurements were calculated using interclass correlation coefficients, and differences with a Kruskal-Wallis test. Significant differences of means between patients and controls were calculated using Mann-Whitney U tests. Significance was assumed at 0.05 adjusted with the Bonferroni method. No significant differences (overall: p = 0.10, patients: 0.51, controls: 0.79) between methods were found. Predicted ICC between the methods ranged from 0.86 to 0.90 with a 95% confidence interval of 0.77-0.94. Differences between patients and controls were significant (p < 0.001) for all three methods. The study offers an alternative 3D approach for calculating patellar tilt comparable to traditional, manual measurements. Furthermore, this analysis offers evidence that a commercially available software can identify the necessary anatomical landmarks for patellar tilt calculation, offering a potential pathway to increased automation of surgical decision-making metrics.

Cerebrovascular diseases (CVD) can lead to stroke and dementia. Stroke is the second leading cause of death world wide and dementia incidence is increasing by the year. There are several markers of CVD that are visible on brain imaging, including: white matter hyperintensities (WMH), acute and chronic ischaemic stroke lesions (ISL), lacunes, enlarged perivascular spaces (PVS), acute and chronic haemorrhagic lesions, and cerebral microbleeds (CMB). Brain atrophy also occurs in CVD. These markers are important for patient management and intervention, since they indicate elevated risk of future stroke and dementia. We systematically reviewed automated systems designed to support radiologists reporting on these CVD imaging findings. We considered commercially available software and research publications which identify at least two CVD markers. In total, we included 29 commercial products and 13 research publications. Two distinct types of commercial support system were available: those which identify acute stroke lesions (haemorrhagic and ischaemic) from computed tomography (CT) scans, mainly for the purpose of patient triage; and those which measure WMH and atrophy regionally and longitudinally. In research, WMH and ISL were the markers most frequently analysed together, from magnetic resonance imaging (MRI) scans; lacunes and PVS were each targeted only twice and CMB only once. For stroke, commercially available systems largely support the emergency setting, whilst research systems consider also follow-up and routine scans. The systems to quantify WMH and atrophy are focused on neurodegenerative disease support, where these CVD markers are also of significance. There are currently no openly validated systems, commercially, or in research, performing a comprehensive joint analysis of all CVD markers (WMH, ISL, lacunes, PVS, haemorrhagic lesions, CMB, and atrophy).

Artificial intelligence (AI) is used increasingly in point-of-care ultrasound (POCUS). However, the true role, utility, advantages, and limitations of AI tools in POCUS have been poorly understood. to conduct a scoping review on the current literature of AI in POCUS to identify (1) how AI is being applied in POCUS, and (2) how AI in POCUS could be utilized in clinical settings. The review followed the JBI scoping review methodology. A search strategy was conducted in Medline, Embase, Emcare, Scopus, Web of Science, Google Scholar, and AI POCUS manufacturer websites. Selection criteria, evidence screening, and selection were performed in Covidence. Data extraction and analysis were performed on Microsoft Excel by the primary investigator and confirmed by the secondary investigators. Thirty-three papers were included. AI POCUS on the cardiopulmonary region was the most prominent in the literature. AI was most frequently used to automatically measure biometry using POCUS images. AI POCUS was most used in acute settings. However, novel applications in non-acute and low-resource settings were also explored. AI had the potential to increase POCUS accessibility and usability, expedited care and management, and had a reasonably high diagnostic accuracy in limited applications such as measurement of Left Ventricular Ejection Fraction, Inferior Vena Cava Collapsibility Index, Left-Ventricular Outflow Tract Velocity Time Integral and identifying B-lines of the lung. However, AI could not interpret poor images, underperformed compared to standard-of-care diagnostic methods, and was less effective in patients with specific disease states, such as severe illnesses that limit POCUS image acquisition. This review uncovered the applications of AI in POCUS and the advantages and limitations of AI POCUS in different clinical settings. Future research in the field must first establish the diagnostic accuracy of AI POCUS tools and explore their clinical utility through clinical trials.

In this work, the CT scans images of lung cancer patients are analysed to diagnose the disease at its early stage. The images are pre-processed using a series of steps such as the Gabor filter, contours to label the region of interest (ROI), increasing the sharpening and cropping of the image. Data augmentation is employed on the pre-processed images using two proposed architectures, namely (1) Convolutional Neural Network (CNN) and (2) Enhanced Integrated model for Lung Tumor Identification (EIM-LTI).•In this study, comparisons are made on non-pre-processed data, Haar and Gabor filters in CNN and the EIM-LTI models. The performance of the CNN and EIM-LTI models is evaluated through metrics such as precision, sensitivity, F1-score, specificity, training and validation accuracy.•The EIM-LTI model's training accuracy is 2.67 % higher than CNN, while its validation accuracy is 2.7 % higher. Additionally, the EIM-LTI model's validation loss is 0.0333 higher than CNN's.•In this study, a comparative analysis of model accuracies for lung cancer detection is performed. Cross-validation with 5 folds achieves an accuracy of 98.27 %, and the model was evaluated on unseen data and resulted in 92 % accuracy.

Focal cortical dysplasia (FCD) is a common cause of pharmacoresistant epilepsy. However, it can be challenging to detect FCD using MRI alone. This study aimed to review and analyze studies that used machine learning and artificial neural networks (ANN) methods as an additional tool to enhance MRI findings in FCD patients. A systematic search was conducted in four databases (Embase, PubMed, Scopus, and Web of Science). The quality of the studies was assessed using QUADAS-AI, and a bivariate random-effects model was used for analysis. The main outcome analyzed was the sensitivity and specificity of patient-wise outcomes. Heterogeneity among studies was assessed using I². A total of 41 studies met the inclusion criteria, including 24 ANN-based studies and 17 machine learning studies. Meta-analysis of internal validation datasets showed a pooled sensitivity of 0.81 and specificity of 0.92 for AI-based models in detecting FCD lesions. Meta-analysis of external validation datasets yielded a pooled sensitivity of 0.73 and specificity of 0.66. There was moderate heterogeneity among studies in the external validation dataset, but no significant publication bias was found. Although there is an increasing number of machine learning and ANN-based models for FCD detection, their clinical applicability remains limited. Further refinement and optimization, along with longitudinal studies, are needed to ensure their integration into clinical practice. Addressing the identified limitations and intensifying research efforts will improve their relevance and reliability in real medical scenarios.